22 Sep 2025 | 5 Mins Read
Zydus shares gain focus on USFDA clearance for oncology unit in Ahmedabad
Flipitmoney
Zydus Lifesciences received an Establishment Inspection Report from the US FDA for its oncology injectable plant, classifying it as "Voluntary Action Indicated" (VAI), a step up from the previous status. Shares ended lower by 1% at Rs 1,038 amid a 13% year-to-date gain, despite the company reporting 3% net profit growth in Q1 and launching USFDA-approved generics.